Business context and reporting period
Filing identity: The request metadata names Kyntra Bio, Inc., but the filing identifies the registrant as FibroGen, Inc. This summary reflects the filing provided. It is FibroGen’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2020.
FibroGen is a biopharmaceutical company developing and commercializing therapies for anemia, fibrotic disease and cancer. Roxadustat was approved in China for CKD-related anemia and in Japan for dialysis patients; its U.S. NDA was accepted for review and its European MAA was accepted in 2020. Pamrevlumab was in Phase 3 development for several indications.
Financial results and liquidity
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | $44.0m | $33.2m | $111.3m | $248.6m |
| Operating costs and expenses | $11.7m | $86.0m | $245.2m | $237.5m |
| Operating income (loss) | $32.3m | ($52.9m) | ($133.9m) | $11.1m |
| Net income (loss) | $33.0m | ($49.4m) | ($130.7m) | $21.2m |
| Basic / diluted EPS | $0.36 / $0.35 | ($0.57) / ($0.57) | ($1.46) / ($1.46) | $0.24 / $0.23 |
Q3 revenue comprised $20.7m development and other revenue, $22.7m net product revenue, and $0.7m drug product revenue; there was no license revenue. Nine-month net product revenue was $43.3m. Overall company margins were not clearly presented in the filing.
Cash and liquidity: Cash and cash equivalents were $532.5m at September 30, 2020, compared with $126.3m at December 31, 2019. Short- and long-term investments totaled $155.6m, and accounts receivable was $26.3m. The company reported $88.8m of operating cash flow for the first nine months, versus $33.7m used in the prior-year period; the 2020 figure reflected working-capital movements, including milestone billing/receipts and deferred revenue, despite the net loss. Investing activities provided $308.7m, primarily from investment maturities. Management said existing cash, investments and receivables should cover anticipated requirements for at least 12 months, while also stating substantial additional funding will be needed in connection with ongoing operations.
Debt and obligations: No conventional borrowings were listed. Finance lease liabilities were $40.8m, with a further $1.2m of operating lease liabilities; product development obligations were $17.8m. Non-cancelable contract commitments totaled $33.1m, including $16.7m for roxadustat supply.
Material changes versus comparable periods
- Q3 revenue rose 33% year over year, largely reflecting higher China roxadustat sales. Nine-month revenue fell 55%, principally because 2019 included substantial collaboration milestone revenue that did not recur in 2020.
- Q3 operating expenses fell sharply, producing quarterly profit. A key driver was an $84.4m reversal of previously accrued AstraZeneca China co-promotion expenses under a July 2020 amendment. Consequently, reported Q3 SG&A was a credit of $49.0m, not a typical positive expense figure.
- Nine-month R&D expense increased 15% to $174.8m, including higher pamrevlumab trial spending and China post-approval studies. Nine-month SG&A declined 24%, mainly reflecting the co-promotion accrual reversal.
- China roxadustat net product revenue increased from $0.6m in the prior-year periods to $22.7m in Q3 2020 and $43.3m for the first nine months of 2020. The filing says comparisons are affected by the product’s recent launch and COVID-19 disruptions.
Outlook, commentary, risks and unusual items
- Regulatory outlook: Management expected an FDA decision on the U.S. roxadustat NDA by its December 20, 2020 goal date, an EMA decision around mid-2021, and a Japan decision on the non-dialysis supplemental application by year-end 2020.
- Development milestones: Management expected topline data from the global Phase 3 roxadustat MDS trial in the first half of 2022; chemotherapy-induced anemia Phase 2 data in the second half of 2021; and pamrevlumab pancreatic cancer and DMD Phase 3 data in the second half of 2022. A second IPF Phase 3 study was planned to start as COVID-19 conditions improved.
- China collaboration changes: FibroGen and AstraZeneca established Falikang, a jointly owned China distribution and commercialization entity. FibroGen retained 51.1% ownership but accounted for Falikang as an equity-method investment because AstraZeneca directs its key commercialization activities. Falikang was expected to become fully operational in early 2021.
- COVID-19: Management reported slower clinical-trial enrollment and some impact on China sales, particularly earlier in the year, but said Q3 financial results were not significantly affected relative to prior quarters. Further effects on trials, supply, sales and operations remained uncertain.
- Accounting and controls: Q3 included $2.1m of net out-of-period revenue reductions, which management deemed immaterial. The company disclosed material weaknesses in risk assessment and controls over drug product shipment identification and variable consideration; disclosure controls were deemed ineffective as of September 30. Management was developing a remediation plan.
- Other risks and contingencies: The filing highlights regulatory and clinical uncertainty, competition, dependence on Astellas and AstraZeneca, China pricing and distribution risks, manufacturing and supply risks, and intellectual-property disputes. A UK court invalidated certain UK designations of FibroGen patents in April 2020; FibroGen and Astellas appealed. No material legal proceedings or material legal accruals were reported.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is FibroGen, Inc., not Kyntra Bio, Inc.
- Assess how much of Q3 profitability depended on the one-time $84.4m co-promotion expense reversal and whether the revised China cost-sharing arrangement changes ongoing economics.
- Track U.S., European and Japanese roxadustat regulatory decisions, including any label, safety or timing limitations.
- Evaluate China sales growth, hospital-listing progress, reimbursement pricing and the transition to Falikang, as well as the impact of rebates and discounts on net revenue.
- Monitor cash use, collaboration funding and management’s stated at-least-12-month liquidity estimate against continuing trial and commercialization spending.
- Follow remediation of the disclosed material weaknesses and review future drug product revenue estimates and out-of-period adjustments.